Azoles

George R. Thompson; Thomas F. Patterson

doi:10.1007/978-90-481-2408-4_15

Azoles

Producción científica: Chapter

Resumen

The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.

Idioma original	English (US)
Título de la publicación alojada	Aspergillosis
Subtítulo de la publicación alojada	From Diagnosis to Prevention
Editorial	Springer Netherlands
Páginas	231-262
Número de páginas	32
ISBN (versión digital)	9789048124084
ISBN (versión impresa)	9789048124077
DOI	https://doi.org/10.1007/978-90-481-2408-4_15
Estado	Published - 2010

ASJC Scopus subject areas

General Medicine

Acceder al documento

10.1007/978-90-481-2408-4_15

Otros archivos y enlaces

Citar esto

@inbook{b47fc9abe9e846a09bf9448ee9a46829,

title = "Azoles",

abstract = "The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.",

keywords = "Albaconazole, Isavuconazole, Itraconazole, Posaconazole, Ravuconazole, Triazoles, Voriconazole",

author = "Thompson, {George R.} and Patterson, {Thomas F.}",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media B.V. 2010.",

year = "2010",

doi = "10.1007/978-90-481-2408-4_15",

language = "English (US)",

isbn = "9789048124077",

pages = "231--262",

booktitle = "Aspergillosis",

publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Azoles

AU - Thompson, George R.

AU - Patterson, Thomas F.

N1 - Publisher Copyright: © Springer Science+Business Media B.V. 2010.

PY - 2010

Y1 - 2010

N2 - The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.

AB - The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.

KW - Albaconazole

KW - Isavuconazole

KW - Itraconazole

KW - Posaconazole

KW - Ravuconazole

KW - Triazoles

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=84919687646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919687646&partnerID=8YFLogxK

U2 - 10.1007/978-90-481-2408-4_15

DO - 10.1007/978-90-481-2408-4_15

M3 - Chapter

AN - SCOPUS:84919687646

SN - 9789048124077

SP - 231

EP - 262

BT - Aspergillosis

PB - Springer Netherlands

ER -

Azoles

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto